RayzeBio (RYZB) is scheduled to resume trading at 7:30 am ET, with quotation set to resume at 7:25 am ET, according to Nasdaq. Shares had been halted for news pending ahead of the company announcing Bristol Myers Squibb (BMY) will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1B, or $3.6B net of estimated cash acquired.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RYZB:
- RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Eight new option listings and one option delisting on November 8th
- RayzeBio to Participate in Upcoming Investor Conferences in November 2023
- RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
Questions or Comments about the article? Write to editor@tipranks.com